
Immune-checkpoint inhibitors (ICIs) and other immunotherapies have revolutionized the treatment of patients with cancer. Nonetheless, most patients do not derive durable benefits, indicating a need for biomarkers to guide treatment selection. This review describes the role of antigen presentation in response to ICIs and other immunotherapies, focusing on the role of molecular and genomic alterations affecting antigen presentation.
Like
Save
Share